What ezetimibe dose do the labels give?
| Product | Strength | Pack |
|---|---|---|
| Zetia (US label) | 10 mg | Bottle of 30 tablets1 |
| Ezetrol (UK SmPC) | 10 mg | Push-through blisters in packs of 7, 10, 14, 20, 28, 30, 50, 84, 90, 98, 100 or 300 tablets; unit dose blisters in packs of 50, 100 or 300 tablets; or bottles of 100; not all pack sizes may be marketed2 |
| Vytorin, ezetimibe with simvastatin (US label) | 10/10 mg (ezetimibe/simvastatin) | Bottles of 30 or 903 |
| Vytorin, ezetimibe with simvastatin (US label) | 10/20 mg, 10/40 mg and 10/80 mg (ezetimibe/simvastatin); the label gives 10/40 mg once daily as the maximum and restricts 10/80 mg daily to adults taking it chronically (12 months or more, for example) without muscle toxicity3 | Bottles of 30 or 903 |
The Zetia label gives ezetimibe as one 10 mg tablet taken orally once daily, with or without food.1
Tablet strengths and form
The table is set at the top of the page
The Zetia label lists tablets as its only dosage form, so it describes no powder or mixing.1
Labelled dose, timing and maximum
The Zetia label gives 10 mg orally once daily, with or without food.1 The UK SmPC gives one 10 mg tablet daily, at any time of day.2 The patient information says it may be easier to remember at the same time every day, such as with breakfast, dinner or at bedtime; a missed dose is taken as soon as possible and the next is not doubled.1
Both give 10 mg once daily and no higher dose.12 The UK SmPC overdose section reports 50 mg a day for up to 14 days in 15 healthy subjects, and 40 mg a day for up to 56 days in 18 patients, as generally well tolerated.2
The Zetia label says no dose change is needed in renal impairment, and it is not recommended in moderate to severe hepatic impairment (Child-Pugh B or C).1 The UK SmPC says no dose adjustment is required for elderly patients.2 The Zetia label lists use with a statin in children 10 years of age and older with heterozygous familial hypercholesterolemia (HeFH).1 The Zetia label also lists use in adults and in pediatric patients 10 years of age and older with homozygous familial hypercholesterolemia (HoFH), and in adults and pediatric patients 9 years of age and older with homozygous familial sitosterolemia.1 The UK SmPC says the safety and efficacy of ezetimibe in children aged 6 to 17 years has not been established and that no recommendation on a posology can be made.2
Use with a statin or other drugs
The Zetia label directs use with a statin or fenofibrate to those products' own labels.1 The UK SmPC says that when ezetimibe is added to a statin, either the usual initial dose of that statin or an already established higher dose is continued, with that statin's own dosage instructions consulted.2 For a bile acid sequestrant, the Zetia label gives ezetimibe at least 2 hours before or 4 hours after it.1
Doses in the main trials
Each of the four trials in the table gave ezetimibe 10 mg with a statin; in ENHANCE the primary outcome measure was the change in the mean carotid-artery intima-media thickness.4567
| Trial | Dose and schedule | People | Length |
|---|---|---|---|
| IMPROVE-IT (Cannon, 2015) | Ezetimibe 10 mg with simvastatin 40 mg once per day, against simvastatin 40 mg with placebo; under the original protocol simvastatin in either arm could be raised to 80 mg if the LDL-C response was inadequate, and a June 2011 protocol amendment stopped new increases to 80 mg48 | 18,144 hospitalized for an acute coronary syndrome within the preceding 10 days4 | Median 6 years4 |
| ENHANCE (Kastelein, 2008) | Ezetimibe 10 mg or placebo, each with simvastatin 80 mg daily5 | 720 with familial hypercholesterolemia5 | 24 months5 |
| SHARP (Baigent) | Simvastatin 20 mg plus ezetimibe 10 mg daily (4650), against matching placebo (4620); patients were first randomised three ways, with a simvastatin 20 mg daily arm, and after 1 year patients on simvastatin alone were rerandomised to simvastatin plus ezetimibe or placebo6 | 9270 with chronic kidney disease, 3023 on dialysis and 6247 not6 | Median 4.9 years6 |
| RACING (Kim, 2022), open-label | Ezetimibe 10 mg with rosuvastatin 10 mg (1894), against rosuvastatin 20 mg alone (1886)7 | 3780 with atherosclerotic cardiovascular disease at 26 centres in South Korea7 | 3-year primary endpoint7 |
Storage
The Zetia label gives storage at 68°F to 77°F (20°C to 25°C), protected from moisture.1 The Vytorin label also gives 68°F to 77°F (20°C to 25°C).3 The UK SmPC gives a shelf life of 3 years and says not to store above 30°C.2
Frequently asked questions
What ezetimibe doses do Milligram users log?
Milligram has no ezetimibe dose share to report from its logs.
How does an ezetimibe dose convert to a U-100 syringe?
It does not, because ezetimibe is a tablet and the label describes no injectable or mixed form.1
Is there a 20 mg ezetimibe dose?
The UK SmPC mentions 20 mg ezetimibe daily in an 8-day interaction study with ciclosporin in twelve healthy subjects.2 The search found no label or human trial of ezetimibe at that dose as a treatment dose.
Is ezetimibe labelled for bodybuilding or steroid cycles?
The search found no label or human trial for use on a steroid cycle or in bodybuilding.
More on ezetimibe and dosing
References
- Organon LLC. These highlights do not include all the information needed to use ZETIA safely and effectively. See full prescribing information for ZETIA. ZETIA ® (ezetimibe) tablets, for oral use Initial U.S. Approval: 2002. 2025. dailymed.nlm.nih.gov
- electronic medicines compendium (UK SmPC). Ezetrol 10mg Tablets - Summary of Product Characteristics (SmPC) - print friendly - (emc). medicines.org.uk
- Organon LLC. These highlights do not include all the information needed to use VYTORIN safely and effectively. See full prescribing information for VYTORIN. VYTORIN ® (ezetimibe and simvastatin) tablets, for oral use Initial U.S. Approval: 2004. 2026. dailymed.nlm.nih.gov
- PubMed. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. 2015. pubmed.ncbi.nlm.nih.gov
- PubMed. Simvastatin with or without ezetimibe in familial hypercholesterolemia. 2008. pubmed.ncbi.nlm.nih.gov
- PMC. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. 2011. pmc.ncbi.nlm.nih.gov
- PubMed. Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial. 2022. pubmed.ncbi.nlm.nih.gov
- ClinicalTrials.gov. NCT00202878: IMPROVE-IT: Examining Outcomes in Subjects With Acute Coronary Syndrome: Vytorin (Ezetimibe/Simvastatin) vs Simvastatin (P04103). 2015. clinicaltrials.gov